Capital Research Global Investors Alnylam Pharmaceuticals, Inc. Transaction History
Capital Research Global Investors
- $440 Billion
- Q1 2025
A detailed history of Capital Research Global Investors transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 7,154,728 shares of ALNY stock, worth $3.11 Billion. This represents 0.44% of its overall portfolio holdings.
Number of Shares
7,154,728
Previous 6,968,513
2.67%
Holding current value
$3.11 Billion
Previous $1.64 Billion
17.82%
% of portfolio
0.44%
Previous 0.35%
Shares
10 transactions
Others Institutions Holding ALNY
# of Institutions
747Shares Held
110MCall Options Held
916KPut Options Held
841K-
Capital World Investors Los Angeles, CA16.7MShares$7.29 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.78 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.15 Billion0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.92 Billion0.79% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.51MShares$1.52 Billion0.12% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $53.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...